Filtered By:
Management: Marketing

This page shows you your search results in order of relevance. This is page number 2.

Order by Relevance | Date

Total 200 results found since Jan 2013.

Efficacy and safety of botulinum toxin type A (Dysport) for the treatment of post-stroke arm spasticity: Results of the German–Austrian open-label post-marketing surveillance prospective study
Abstract: The current practice in Germany and Austria, and the safety and efficacy of botulinum toxin type A (BoNT-A; Dysport) in the treatment of patients with post-stroke arm spasticity (with no fixed upper-limb contractures), were assessed in this observational prospective non-interventional study. One treatment cycle was documented with assessments at baseline, approximately week 4 (optional), and approximately week 12. Pattern of spasticity, treatment goal, safety and efficacy were recorded. Overall response and goal achievement was rated on a 4-point scale (‘no goal achievement’, ‘goal achievement’, ‘good g...
Source: Journal of the Neurological Sciences - December 23, 2013 Category: Neurology Authors: Wolfgang H. Jost, Harald Hefter, Andrea Reissig, Katja Kollewe, Joerg Wissel Tags: Original Articles Source Type: research

BOTOX(R) (Botulinum Toxin Type A) Receives a Positive Opinion in Fourteen European Countries for the Treatment of Focal Spasticity of the Ankle in Adult Post Stroke Patients
This Positive Opinion Paves the Way for a Second Indication for BOTOX® in Adult Spasticity Associated with Stroke MARLOW, England, May 1, 2014 -- (Healthcare Sales & Marketing Network) --Today, Allergan Inc. announced that BOTOX® has received a... Biopharmaceuticals, RegulatoryAllergan, BOTOX, Adult Spasticity, limb spasticity, stroke
Source: HSMN NewsFeed - May 1, 2014 Category: Pharmaceuticals Source Type: news

Ekso GT(TM) Robotic Exoskeleton Cleared by FDA for Use With Stroke and Spinal Cord Injury Patients
First robotic exoskeleton cleared for use with stroke and spinal cord injury levels to C7 RICHMOND, Calif., April 04, 2016 -- (Healthcare Sales & Marketing Network) -- Ekso Bionics Holdings, Inc. (EKSO), a robotic exoskeleton company, today announced th... Devices, Neurology, FDAEkso Bionics, robotic exoskeleton, Ekso GT, stroke
Source: HSMN NewsFeed - April 4, 2016 Category: Pharmaceuticals Source Type: news

Creative Medical Technology Holdings Files Patent on AmnioStem Stroke Therapy
PHOENIX and SAN DIEGO, Dec. 13, 2016 -- (Healthcare Sales & Marketing Network) -- Creative Medical Technology Holdings (the "Company") (CELZ) announced today filing of US patent application #62/400557 entitled "Treatment of Stroke by Amniot... Regenerative Medicine, Neurology Creative Medical Technology, AmnioStem, stem cell, exosomes, stroke
Source: HSMN NewsFeed - December 13, 2016 Category: Pharmaceuticals Source Type: news

Codman Neuro Announces Acquisition Of Neuravi Limited To Accelerate Innovation In Acute Ischemic Stroke Therapy
Second Acquisition in Months Demonstrates Commitment to Addressing Unmet Needs in Stroke IRVINE, Calif., April 10, 2017 -- (Healthcare Sales & Marketing Network) -- Codman Neuro today announced the acquisition of Neuravi Limited, a privately held Irish... Devices, Neurology, Interventional, Mergers & Acquisitions Codman, Johnson & Johnson, Neuravi Limited, EmboTrap, stroke
Source: HSMN NewsFeed - April 10, 2017 Category: Pharmaceuticals Source Type: news

Sensome, Formerly Instent, Raises €4.7m to Bring the World's First Connected Stroke Guidewire to Patients
Sensome's first application of its AI-powered micro-sensor technology can detect the composition of the blockage in the brain during stroke treatment PARIS, July 17, 2017 -- (Healthcare Sales & Marketing Network) -- Sensome, formerly Instent, a company... Devices, Interventional, Venture Capital Sensome, Instent , guidewire, stroke
Source: HSMN NewsFeed - July 17, 2017 Category: Pharmaceuticals Source Type: news

New Study Shows Superiority of Intrathecal Baclofen Therapy (ITB Therapy(SM)) Over Oral Medication for the Treatment of Severe Post-Stroke Spasticity
Therapy Delivered via the Medtronic SynchroMed(TM) II Infusion System DUBLIN - January 11, 2018 -- (Healthcare Sales & Marketing Network) -- Medtronic plc (NYSE:MDT) today announced the publication of results from the 'Spasticity In Stroke-Randomised St... Devices, Drug Delivery, Neurology Medtronic, Intrathecal Baclofen Therapy, baclofen, SynchroMed, Stroke
Source: HSMN NewsFeed - January 11, 2018 Category: Pharmaceuticals Source Type: news

2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials.
senfield K, Domanski MJ, Lansky AJ, McMurray JJV, Tcheng JE, Steinhubl SR, Burton P, Mauri L, O'Connor CM, Pfeffer MA, Hung HMJ, Stockbridge NL, Chaitman BR, Temple RJ, Standardized Data Collection for Cardiovascular Trials Initiative (SCTI) Abstract This publication describes uniform definitions for cardiovascular and stroke outcomes developed by the Standardized Data Collection for Cardiovascular Trials Initiative and the US Food and Drug Administration (FDA). The FDA established the Standardized Data Collection for Cardiovascular Trials Initiative in 2009 to simplify the design and conduct of clinical trials in...
Source: Circulation - February 27, 2018 Category: Cardiology Authors: Hicks KA, Mahaffey KW, Mehran R, Nissen SE, Wiviott SD, Dunn B, Solomon SD, Marler JR, Teerlink JR, Farb A, Morrow DA, Targum SL, Sila CA, Hai MTT, Jaff MR, Joffe HV, Cutlip DE, Desai AS, Lewis EF, Gibson CM, Landray MJ, Lincoff AM, White CJ, Brooks SS, R Tags: Circulation Source Type: research

ReWalk Robotics Receives CE Mark for ReStore(TM) Exo-Suit Stroke Rehabilitation Device
Advent of the Soft Exo-Suit Generation expands assistive robotic therapy for stroke survivors MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, May 29, 2019 -- (Healthcare Sales & Marketing Network) -- ReWalk Robotics, Ltd. (Nasdaq: RWLK) ("ReWalk"... Devices, Regulatory ReWalk Robotics, exo-suit, stroke
Source: HSMN NewsFeed - May 29, 2019 Category: Pharmaceuticals Source Type: news

Artificial Neural Network Analyzing Wearable Device Gait Data for Identifying Patients With Stroke Unable to Return to Work
A potential dramatic effect of long-term disability due to stroke is the inability to return to work. An accurate prognosis and the identification of the parameters inflating the possibility of return to work after neurorehabilitation are crucial. Many factors may influence it, such as mobility and, in particular, walking ability. In this pilot study, two emerging technologies have been combined with the aim of developing a prognostic tool for identifying patients able to return to work: a wearable inertial measurement unit for gait analysis and an artificial neural network (ANN). Compared with more conventional statistics...
Source: Frontiers in Neurology - May 19, 2021 Category: Neurology Source Type: research

RapidPulse Raises Additional Funding for Ischemic Stroke Therapies and Notes Promising Results
MIAMI, Sept. 13, 2022 -- (Healthcare Sales & Marketing Network) -- RapidPulse, Inc., a privately-held medical device company developing a novel aspiration system to treat ischemic stroke, today announced that it has raised an additional $10.5 million, bri... Devices, Interventional, Neurology, Venture Capital RapidPulse, Cyclic Aspiration System, stroke
Source: HSMN NewsFeed - September 13, 2022 Category: Pharmaceuticals Source Type: news

Reach Neuro Receives FDA Breakthrough Device Designation for Device to Restore Arm and Hand Movement to Chronic Stroke Patients
Reach Neuro's Avantis device delivers small electrical impulses to the spinal cord to help stroke survivors regain motion and independence PITTSBURGH, April 10, 2023 -- (Healthcare Sales & Marketing Network) -- Reach Neuro, Inc., a neurotechnology comp... Devices, Neurology, FDA Reach Neuro, Avantis, stroke
Source: HSMN NewsFeed - April 10, 2023 Category: Pharmaceuticals Source Type: news

BioTime Enters into Worldwide License Agreement with UCLA to Develop Therapy for the Treatment of Stroke
ALAMEDA, Calif.--(Healthcare Sales & Marketing Network)--BioTime, Inc. (NYSE MKT: BTX) today announced that it has entered into an exclusive license agreement with the University of California, Los Angeles (UCLA) for novel technology related to the treatme... Regenerative Medicine, Neurology, LicensingBioTime, HyStem hydrogel, stroke, stem cell
Source: HSMN NewsFeed - April 19, 2013 Category: Pharmaceuticals Source Type: news

In a Subanalysis, Eliquis(R) (apixaban) Reduced the Risk of Stroke and Demonstrated Fewer Major Bleeding Events versus Warfarin Consistently across Age Groups, Including Older Patients with Nonvalvular Atrial Fibrillation
Data from Phase 3 ARISTOTLE trial pre-specified subanalysis published in the European Heart Journal PRINCETON, N.J. & NEW YORK--(Healthcare Sales & Marketing Network)--Bristol-Myers Squibb Company (BMY) and Pfizer Inc. (PFE) today announced results of a... Biopharmaceuticals, CardiologyBristol-Myers Squibb, Pfizer, Eliquis, apixaban, atrial fibrillation, stroke
Source: HSMN NewsFeed - February 21, 2014 Category: Pharmaceuticals Source Type: news

Retrospective Safety and Efficacy of the DeepTMS in a variety of pathologies including refractory Major Depression, Bipolar Depression, Parkinsońs Disease, negative symptoms of Schizophrenia and Stroke in a clinical setting; an update on the post-Marketing experience in Chile
Repetitive transcranial magnetic stimulation (rTMS) has been proposed as add-on for the treatment of various pathologies, including refractory Major Depression (MD), Bipolar Depression (BD), Parkinsońs Disease (PD), negative symptoms of Schizophrenia (NS) and Stroke (ST). However, the effectiveness of the conventional rTMS in clinical settings is currently being debated. The novel Deep TMS H-coils can effectively stimulate deeper and larger brain regions than conventional rTMS coils, including the complete thickness of motor and prefrontal cortices, suggesting greater potential clinical efficacy.
Source: BRAIN STIMULATION: Basic, Translational, and Clinical Research in Neuromodulation - September 1, 2014 Category: Neurology Authors: Jimmy Stehberg, Francisco Torres, Esteban Villalón, Raúl Riquelme Tags: Poster Source Type: research